ATIR (Allodepleted T-cell ImmunotheRapeutics) is designed to support the patient’s newly transplanted immune system before it becomes fully functional. In ATIR, T-cells causing Graft-versus-Host-Disease (GVHD) have been depleted, while T-cells protective against tumor cells and infections have been retained. This provides physicians with the opportunity to infuse potent T-cells with minimal risk of causing potential lethal severe GVHD. ATIR therefore addresses one of the biggest challenges of using haploidentical family members as stem cell donors for those patients that would otherwise not find a matching donor in time.
The Company’s lead product, ATIR101, addresses key risks and limitations of HSCT in blood cancers, specifically GVHD and cancer relapse. The Company’s second product, ATIR201, is expected to address the key risks and limitations of HSCT in inherited blood disorders: opportunistic infections, GVHD and limited donor availability.
ATIR101 and ATIR201 are cellular products for infusion. They consist of donor lymphocytes (immune cells), specifically manufactured for each individual patient from a healthy, haploidentical stem cell donor.
Using the Company’s proprietary selective cytotoxic compound, TH9402, those T-cells which attack the patient, causing Graft-versus-Host Disease (GVHD), are depleted. The full immune repertoire of other donor immune cells, including immunological memory, is retained in the final product.